【摘要】：目的分析耐甲氧西林金黃色葡萄球菌(MRSA)SCCmec基因型別及耐藥性,為不同感染型別菌株的有效治療及耐藥性控制提供指導(dǎo)。方法收集本院2016年1-12月患者各類送檢臨床標(biāo)本,分離MRSA,對(duì)菌株進(jìn)行SCCmec基因的多重PCR擴(kuò)增,K-B法分析SCCmec基因型菌株耐藥情況,根據(jù)標(biāo)準(zhǔn)判定結(jié)果。結(jié)果本院2016年1-12月患者各類臨床標(biāo)本中共分離出MRSA 282株,攜帶SCCmec基因151株,占53.55%,其中143株攜帶SCCmecⅢ型基因,8株攜帶SCCmecⅡ型基因。攜帶SCCmecⅢ型基因MRSA病區(qū)分布:ICU病房81株(占56.64%),外科病房39株(占27.27%),內(nèi)科病房16株(占11.19%),門診病房7株(占4.90%)。攜帶SCCmecⅡ型基因MRSA病區(qū)分布:ICU病房5株(占62.50%),外科病房2株(占25.00%),內(nèi)科病房1株(占12.50%),門診病房分離的MRSA菌株未檢出SCCmecⅡ型。攜帶SCCmecⅢ型基因的MRSA標(biāo)本來(lái)源:痰液93株(占65.03%),血液37株(占25.87%),腹水9株(占6.29%),尿液3株(占2.10%),傷口分泌物1株(占0.70%)。攜帶SCCmecⅡ型基因MRSA標(biāo)本來(lái)源:痰液5株(占62.50%),血液3株(占37.50%),患者腹水、尿液標(biāo)本以及傷口分泌物標(biāo)本分離的MRSA菌株未檢出SCCmecⅡ型。攜帶SCCmecⅢ型MRSA對(duì)氨芐西林、阿莫西林、哌拉西林、頭孢拉啶、頭孢吡肟和利福平的耐藥率分別為100.00%、67.83%、53.85%、60.13%、26.57%和8.39%,對(duì)萬(wàn)古霉素敏感;攜帶SCCmecⅡ型MRSA對(duì)氨芐西林、阿莫西林、哌拉西林、頭孢拉啶、頭孢吡肟和利福平的耐藥率分別為100.00%、75.00%、37.50%、25.00%、12.50%和12.50%,對(duì)萬(wàn)古霉素敏感。結(jié)論 MRSA臨床分離株基因型以SCCmecⅢ型為主,主要分離自醫(yī)院的ICU病房及患者的痰液和血液標(biāo)本。臨床治療MRSA感染時(shí)應(yīng)首選萬(wàn)古霉素,但應(yīng)合理選用,避免耐藥性發(fā)展。
[Abstract]:Objective to analyze the (MRSA) SCCmec genotypes and drug resistance of methicillin-resistant Staphylococcus aureus, and to provide guidance for the effective treatment and drug resistance control of different infection types of Staphylococcus aureus. Methods from January to December 2016, we collected all kinds of clinical samples of patients from January to December of 2016, isolated MRSA, and analyzed the drug resistance of SCCmec genotypes by multiplex PCR amplification of SCCmec gene by K-B method. Results A total of 282 strains of MRSA were isolated from clinical specimens from January to December 2016 in our hospital, and 151 strains were carrying SCCmec gene, accounting for 53.555.Among them, 143 strains carried SCCmec 鈪，

本文編號(hào)：2236169